- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05174065
Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)
January 30, 2024 updated by: Amgen
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Apremilast (AMG 407) in Japanese Subjects With Palmoplantar Pustulosis (PPP)
The primary objective of the study is to evaluate the efficacy of apremilast (AMG 407) twice daily (BID) compared with placebo in participants with Palmoplantar Pustulosis (PPP).
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
176
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Aichi
-
Nagakute-shi, Aichi, Japan, 480-1195
- Aichi Medical University Hospital
-
Nagoya-shi, Aichi, Japan, 467-8602
- Nagoya City University Hospital
-
-
Chiba
-
Sakura-shi, Chiba, Japan, 285-8741
- Toho University Sakura Medical Center
-
-
Ehime
-
Toon-shi, Ehime, Japan, 791-0295
- Ehime University Hospital
-
-
Fukuoka
-
Fukuoka-shi, Fukuoka, Japan, 814-0180
- Fukuoka University Hospital
-
Fukuoka-shi, Fukuoka, Japan, 811-1302
- Kusuhara Dermatology Clinic
-
Kasuga-shi, Fukuoka, Japan, 816-0802
- Higuchi Dermatology Urology Clinic
-
Kurume-shi, Fukuoka, Japan, 830-0011
- Kurume University Hospital
-
Ogori-shi, Fukuoka, Japan, 838-0144
- Nagata Dermatology Clinic
-
-
Fukushima
-
Fukushima-shi, Fukushima, Japan, 960-1295
- Fukushima Medical University Hospital
-
-
Gifu
-
Minokamo-shi, Gifu, Japan, 505-8510
- Central Japan International Medical Center
-
-
Hokkaido
-
Asahikawa-shi, Hokkaido, Japan, 070-0810
- Motomachi Dermatology Clinic
-
Asahikawa-shi, Hokkaido, Japan, 078-8510
- Asahikawa Medical University Hospital
-
Chitose-shi, Hokkaido, Japan, 066-0021
- Medical corporation kojinkai Chitose dermatology and plastic surgery clinic
-
Sapporo-shi, Hokkaido, Japan, 060-0063
- Medical Corporation Kojinkai Sapporo Skin Clinic
-
Sapporo-shi, Hokkaido, Japan, 002-8022
- Shinoro Dermatology Clinic
-
Sapporo-shi, Hokkaido, Japan, 003-0833
- Medical Corporation Kojinkai Kitago Dermatology Clinic
-
Sapporo-shi, Hokkaido, Japan, 006-0022
- Shibaki Dermatology Clinic
-
-
Hyogo
-
Kobe-shi, Hyogo, Japan, 650-0017
- Kobe University Hospital
-
-
Ibaraki
-
Mito-shi, Ibaraki, Japan, 310-0015
- Mito Kyodo General Hospital
-
-
Ishikawa
-
Kanazawa-shi, Ishikawa, Japan, 920-8530
- Ishikawa Prefectural Central Hospital
-
-
Kagawa
-
Takamatsu-shi, Kagawa, Japan, 760-0017
- Takamatsu Red Cross Hospital
-
-
Kagoshima
-
Kagoshima-shi, Kagoshima, Japan, 890-8520
- Kagoshima University Hospital
-
-
Kanagawa
-
Yokohama-shi, Kanagawa, Japan, 221-0825
- Nomura Dermatology Clinic
-
-
Kochi
-
Nankoku-shi, Kochi, Japan, 783-8505
- Kochi Medical School Hospital
-
-
Niigata
-
Nagaoka-shi, Niigata, Japan, 940-2085
- Nagaoka Red Cross Hospital
-
-
Oita
-
Yufu-shi, Oita, Japan, 879-5593
- Oita University Hospital
-
-
Osaka
-
Osaka-shi, Osaka, Japan, 550-0006
- Nippon Life Hospital
-
Osaka-shi, Osaka, Japan, 554-0021
- Medical Corporation Goto Dermatology Clinic
-
Sakai-shi, Osaka, Japan, 593-8324
- Dermatology and Ophthalmology Kume Clinic
-
Takatsuki-shi, Osaka, Japan, 569-0824
- Yoshikawa Skin Clinic
-
-
Saitama
-
Koshigaya-shi, Saitama, Japan, 343-8555
- Dokkyo Medical University Saitama Medical Center
-
Saitama-shi, Saitama, Japan, 330-0064
- Pansy Skin Clinic
-
-
Tochigi
-
Shimotsuke-shi, Tochigi, Japan, 329-0498
- Jichi Medical University Hospital
-
-
Tokyo
-
Chiyoda-ku, Tokyo, Japan, 102-8798
- Tokyo Teishin Hospital
-
Itabashi-ku, Tokyo, Japan, 173-8610
- Nihon University Itabashi Hospital
-
Itabashi-ku, Tokyo, Japan, 173-8606
- Teikyo University Hospital
-
Shinjuku-ku, Tokyo, Japan, 160-0023
- Tokyo Medical University Hospital
-
Shinjuku-ku, Tokyo, Japan, 161-8521
- Seibo International Catholic Hospital
-
-
Yamanashi
-
Kofu-shi, Yamanashi, Japan, 400-8506
- Yamanashi Prefectural Central Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria
- Japanese participants ≥ 18 years of age upon entry into initial screening
- Palmoplantar pustulosis diagnosis with or without pustulotic arthro-osteitis (PAO) for no less than 24 weeks
- PPPASI total score of ≥12 at screening and at baseline
- Moderate or severe pustules/vesicles on palms or soles (PPPASI severity score ≥2) at screening and at baseline
- Inadequate response (defined as repeated relapsing-remitting in the same location for a 24-week period) to topical treatments prior to or at screening
Key Exclusion Criteria
- Changes in disease severity during screening (PPPASI total score change ≥ 5 improvement, from screening to baseline)
- Periodontitis requiring treatment
- Chronic or recurrent tonsillitis or sinusitis requiring any continuous treatment
- Has a diagnosis of plaque-type psoriasis at baseline
- Has the presence of pustular psoriasis on any part of the body other than the palms and soles
- Has evidence of skin conditions of hand and feet at baseline that would interfere with evaluations of the effect of Investigational Product
- Has unstable cardiovascular disease, defined as a recent clinical deterioration or a cardiac hospitalization within 12 weeks prior to screening
- Malignancy or history of malignancy
- Participant has received any procedures for focal infection within 24 weeks of baseline
- Female participants who are breastfeeding or who plan to breastfeed while on study
- Female participants of childbearing potential with a positive pregnancy test
- Had prior treatment with apremilast
- Has a prior medical history of suicide attempt at any time in the participant's lifetime prior to signing of informed consent or randomization, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing of informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Apremilast
Apremilast will be administered to participants twice daily (BID)
|
Oral tablets
Other Names:
|
Experimental: Placebo and Apremilast
Matching placebo will be administered to participants twice daily (BID) until week 16.
After week 16, Apremilast will be administered to participants BID.
|
Oral tablets
Oral tablets
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants achieving at least 50% reduction from baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) total score (PPPASI-50) at week 16
Time Frame: 16 weeks
|
PPPASI is a disease-specific efficacy assessment tool used by Investigators established to detect a change of disease status on palms or soles.
PPPASI produces numeric scores that can range from 0 to 72.
A higher score indicates more severe disease.
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in PPPASI total score at week 16
Time Frame: 16 weeks
|
16 weeks
|
|
Change from baseline in Palmoplantar Pustulosis Severity Index (PPSI) total score at week 16
Time Frame: 16 weeks
|
PPSI is a disease-specific efficacy assessment established to detect a change of disease status on a specified palm or sole. PPSI produces numeric scores that can range from 0 to 12. A higher score indicates more severe disease. |
16 weeks
|
Change from baseline in Visual Analogue Scale (VAS) assessment for Palmoplantar Pustulosis (PPP) symptoms (pruritis and pain/discomfort) at week 16
Time Frame: 16 weeks
|
Participants will use VAS (with scores ranging from 0 to 100, with 100 being most severe) to assess the degree of PPP pruritis and pain/discomfort and on the hands and feet
|
16 weeks
|
Change from Baseline in Dermatology Life Quality Index (DLQI) total score at week 16
Time Frame: 16 weeks
|
DLQI is a skin disease-specific Quality of Life (QoL) questionnaire comprised of 10 items assessing the participant's status over the previous week.
A numeric score ranging from 0 to 30 is produced with higher scores indicating increased disease severity
|
16 weeks
|
Number of participants with treatment-emergent adverse events
Time Frame: 56 weeks
|
56 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: MD, Amgen
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 8, 2022
Primary Completion (Actual)
August 19, 2023
Study Completion (Estimated)
June 6, 2024
Study Registration Dates
First Submitted
December 14, 2021
First Submitted That Met QC Criteria
December 14, 2021
First Posted (Actual)
December 30, 2021
Study Record Updates
Last Update Posted (Estimated)
February 1, 2024
Last Update Submitted That Met QC Criteria
January 30, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Skin Diseases, Papulosquamous
- Psoriasis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Phosphodiesterase Inhibitors
- Phosphodiesterase 4 Inhibitors
- Apremilast
Other Study ID Numbers
- 20200195
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD Sharing Time Frame
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities.
There is no end date for eligibility to submit a data sharing request for this study.
IPD Sharing Access Criteria
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s).
In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling.
Requests are reviewed by a committee of internal advisors.
If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision.
Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement.
This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications.
Further details are available at the URL below.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Palmoplantar Pustulosis
-
AbbVieCompleted
-
Boehringer IngelheimCompletedPalmoplantar Pustulosis (PPP)United Kingdom, Korea, Republic of, United States, Canada, Belgium, Australia, Taiwan, Japan, France, Germany, Russian Federation, Hungary, Netherlands, Czechia, Poland
-
AmgenCompletedPalmoplantaris PustulosisJapan
-
Janssen Pharmaceutical K.K.Completed
-
Lenzi Egisto S.P.A.TerminatedPustulosis of Palms and SolesItaly
-
Janssen Pharmaceutical K.K.Active, not recruiting
-
Boehringer IngelheimTerminatedPalmoplantar PustulosisUnited Kingdom, Korea, Republic of, United States, Canada, Belgium, Australia, Taiwan, Japan, France, Germany, Russian Federation, Czechia, Hungary, Poland
-
Baylor Research InstituteJanssen Services, LLC; Dermatology Research InstituteCompleted
-
Brigham and Women's HospitalUniversity of PennsylvaniaRecruiting
-
Aristea Therapeutics, Inc.TerminatedPalmoplantar PustulosisUnited States, Canada, Germany, Poland, Czechia, Hungary, United Kingdom
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States